Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 1.05 billion. The enterprise value is 998.73 million.
| Market Cap | 1.05B |
| Enterprise Value | 998.73M |
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 706.25 million shares outstanding. The number of shares has increased by 11.25% in one year.
| Current Share Class | 706.25M |
| Shares Outstanding | 706.25M |
| Shares Change (YoY) | +11.25% |
| Shares Change (QoQ) | +50.75% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 21.01% |
| Float | 695.28M |
Valuation Ratios
The trailing PE ratio is 433.52 and the forward PE ratio is 57.04.
| PE Ratio | 433.52 |
| Forward PE | 57.04 |
| PS Ratio | 3.29 |
| PB Ratio | 4.46 |
| P/TBV Ratio | 8.73 |
| P/FCF Ratio | 22.91 |
| P/OCF Ratio | 22.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.83, with an EV/FCF ratio of 21.73.
| EV / Earnings | 411.31 |
| EV / Sales | 3.12 |
| EV / EBITDA | 26.83 |
| EV / EBIT | 35.13 |
| EV / FCF | 21.73 |
Financial Position
The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.59 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 2.15 |
| Interest Coverage | 3.06 |
Financial Efficiency
Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 2.92%.
| Return on Equity (ROE) | 1.02% |
| Return on Assets (ROA) | 4.55% |
| Return on Invested Capital (ROIC) | 2.92% |
| Return on Capital Employed (ROCE) | 8.53% |
| Weighted Average Cost of Capital (WACC) | 4.66% |
| Revenue Per Employee | 787,109 |
| Profits Per Employee | 5,966 |
| Employee Count | 407 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 0.75 |
Taxes
In the past 12 months, Pharming Group has paid 8.78 million in taxes.
| Income Tax | 8.78M |
| Effective Tax Rate | 80.25% |
Stock Price Statistics
The stock price has increased by +106.03% in the last 52 weeks. The beta is 0.12, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +106.03% |
| 50-Day Moving Average | 1.39 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 57.49 |
| Average Volume (20 Days) | 13,530,674 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 320.35 million and earned 2.43 million in profits. Earnings per share was 0.00.
| Revenue | 320.35M |
| Gross Profit | 281.60M |
| Operating Income | 27.90M |
| Pretax Income | 10.94M |
| Net Income | 2.43M |
| EBITDA | 33.74M |
| EBIT | 27.90M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 152.54 million in cash and 98.61 million in debt, with a net cash position of 53.93 million or 0.08 per share.
| Cash & Cash Equivalents | 152.54M |
| Total Debt | 98.61M |
| Net Cash | 53.93M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 236.01M |
| Book Value Per Share | 0.34 |
| Working Capital | 156.44M |
Cash Flow
In the last 12 months, operating cash flow was 46.59 million and capital expenditures -637,923, giving a free cash flow of 45.96 million.
| Operating Cash Flow | 46.59M |
| Capital Expenditures | -637,923 |
| Depreciation & Amortization | 5.83M |
| Net Borrowing | -3.61M |
| Free Cash Flow | 45.96M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 87.90%, with operating and profit margins of 8.71% and 0.76%.
| Gross Margin | 87.90% |
| Operating Margin | 8.71% |
| Pretax Margin | 3.42% |
| Profit Margin | 0.76% |
| EBITDA Margin | 10.53% |
| EBIT Margin | 8.71% |
| FCF Margin | 14.35% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.25% |
| Shareholder Yield | -11.25% |
| Earnings Yield | 0.23% |
| FCF Yield | 4.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.84 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 5 |